Further evaluation of a mutagen-attenuated Rift Valley fever vaccine in sheep

J. C. Morrill, L. Carpenter, D. Taylor, H. H. Ramsburg, J. Quance, C. J. Peters

Research output: Contribution to journalArticle

83 Citations (Scopus)

Abstract

A previous study demonstrated that a mutagen-attenuated Rift Valley fever virus (RVFV) vaccine, RVF MP-12, was immunogenic and non-abortogenic when ewes, 90 110 days pregnant, were inoculated with 5 × 105 plaque-forming units (p.f.u.) of the virus strain. The ewes delivered live, healthy lambs that had no neutralizing antibody to RVFV until after they had ingested colostrum. To assess further the safety and protective capability of this candidate vaccine, six pregnant ewes were inoculated with 5 × 103 p.f.u. of RVF MP-12 and challenged with 5 × 105 p.f.u. of virulent ZH-501 strain of RVFV 30 days later. No viraemia was detected after vaccination or challenge and all six ewes delivered live, healthy lambs. Those lambs tested before their nursing did not have neutralizing antibody to RVFV but quickly acquired antibody titres of 1:320 to ≥ 1:10 240 after ingesting colostrum. To test the safety of the RVF MP-12 immunogen in neonates, lambs ≤ 7 days old, born to unvaccinated ewes, were inoculated with 5 × 105 p.f.u. of RVF MP-12. With the exception of brief pyrexia in 18 of 26 lambs, and a transient low-titred viraemia in 16 of 26 lambs after inoculation, no untoward effects were observed. Serum-neutralizing antibody to RVFV was detected 5-7 days after inoculation. Lambs vaccinated with either 5 × 105 or 5 × 103 p.f.u. of RVF MP-12 were protected against virulent RVFV challenge at 14 days postvaccination.

Original languageEnglish (US)
Pages (from-to)35-41
Number of pages7
JournalVaccine
Volume9
Issue number1
DOIs
StatePublished - 1991
Externally publishedYes

Fingerprint

Rift Valley Fever
Rift Valley fever virus
Rift Valley fever
Mutagens
Sheep
lambs
Vaccines
vaccines
sheep
ewes
Neutralizing Antibodies
neutralizing antibodies
Colostrum
Viremia
viremia
vaccination
colostrum
Safety
Vaccination
Nursing

Keywords

  • attenuated
  • mutagen
  • Rift Valley fever
  • sheep
  • vaccine

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Cite this

Morrill, J. C., Carpenter, L., Taylor, D., Ramsburg, H. H., Quance, J., & Peters, C. J. (1991). Further evaluation of a mutagen-attenuated Rift Valley fever vaccine in sheep. Vaccine, 9(1), 35-41. https://doi.org/10.1016/0264-410X(91)90314-V

Further evaluation of a mutagen-attenuated Rift Valley fever vaccine in sheep. / Morrill, J. C.; Carpenter, L.; Taylor, D.; Ramsburg, H. H.; Quance, J.; Peters, C. J.

In: Vaccine, Vol. 9, No. 1, 1991, p. 35-41.

Research output: Contribution to journalArticle

Morrill, JC, Carpenter, L, Taylor, D, Ramsburg, HH, Quance, J & Peters, CJ 1991, 'Further evaluation of a mutagen-attenuated Rift Valley fever vaccine in sheep', Vaccine, vol. 9, no. 1, pp. 35-41. https://doi.org/10.1016/0264-410X(91)90314-V
Morrill JC, Carpenter L, Taylor D, Ramsburg HH, Quance J, Peters CJ. Further evaluation of a mutagen-attenuated Rift Valley fever vaccine in sheep. Vaccine. 1991;9(1):35-41. https://doi.org/10.1016/0264-410X(91)90314-V
Morrill, J. C. ; Carpenter, L. ; Taylor, D. ; Ramsburg, H. H. ; Quance, J. ; Peters, C. J. / Further evaluation of a mutagen-attenuated Rift Valley fever vaccine in sheep. In: Vaccine. 1991 ; Vol. 9, No. 1. pp. 35-41.
@article{7351691cbb2d42c69f9ca886a3e83094,
title = "Further evaluation of a mutagen-attenuated Rift Valley fever vaccine in sheep",
abstract = "A previous study demonstrated that a mutagen-attenuated Rift Valley fever virus (RVFV) vaccine, RVF MP-12, was immunogenic and non-abortogenic when ewes, 90 110 days pregnant, were inoculated with 5 × 105 plaque-forming units (p.f.u.) of the virus strain. The ewes delivered live, healthy lambs that had no neutralizing antibody to RVFV until after they had ingested colostrum. To assess further the safety and protective capability of this candidate vaccine, six pregnant ewes were inoculated with 5 × 103 p.f.u. of RVF MP-12 and challenged with 5 × 105 p.f.u. of virulent ZH-501 strain of RVFV 30 days later. No viraemia was detected after vaccination or challenge and all six ewes delivered live, healthy lambs. Those lambs tested before their nursing did not have neutralizing antibody to RVFV but quickly acquired antibody titres of 1:320 to ≥ 1:10 240 after ingesting colostrum. To test the safety of the RVF MP-12 immunogen in neonates, lambs ≤ 7 days old, born to unvaccinated ewes, were inoculated with 5 × 105 p.f.u. of RVF MP-12. With the exception of brief pyrexia in 18 of 26 lambs, and a transient low-titred viraemia in 16 of 26 lambs after inoculation, no untoward effects were observed. Serum-neutralizing antibody to RVFV was detected 5-7 days after inoculation. Lambs vaccinated with either 5 × 105 or 5 × 103 p.f.u. of RVF MP-12 were protected against virulent RVFV challenge at 14 days postvaccination.",
keywords = "attenuated, mutagen, Rift Valley fever, sheep, vaccine",
author = "Morrill, {J. C.} and L. Carpenter and D. Taylor and Ramsburg, {H. H.} and J. Quance and Peters, {C. J.}",
year = "1991",
doi = "10.1016/0264-410X(91)90314-V",
language = "English (US)",
volume = "9",
pages = "35--41",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "1",

}

TY - JOUR

T1 - Further evaluation of a mutagen-attenuated Rift Valley fever vaccine in sheep

AU - Morrill, J. C.

AU - Carpenter, L.

AU - Taylor, D.

AU - Ramsburg, H. H.

AU - Quance, J.

AU - Peters, C. J.

PY - 1991

Y1 - 1991

N2 - A previous study demonstrated that a mutagen-attenuated Rift Valley fever virus (RVFV) vaccine, RVF MP-12, was immunogenic and non-abortogenic when ewes, 90 110 days pregnant, were inoculated with 5 × 105 plaque-forming units (p.f.u.) of the virus strain. The ewes delivered live, healthy lambs that had no neutralizing antibody to RVFV until after they had ingested colostrum. To assess further the safety and protective capability of this candidate vaccine, six pregnant ewes were inoculated with 5 × 103 p.f.u. of RVF MP-12 and challenged with 5 × 105 p.f.u. of virulent ZH-501 strain of RVFV 30 days later. No viraemia was detected after vaccination or challenge and all six ewes delivered live, healthy lambs. Those lambs tested before their nursing did not have neutralizing antibody to RVFV but quickly acquired antibody titres of 1:320 to ≥ 1:10 240 after ingesting colostrum. To test the safety of the RVF MP-12 immunogen in neonates, lambs ≤ 7 days old, born to unvaccinated ewes, were inoculated with 5 × 105 p.f.u. of RVF MP-12. With the exception of brief pyrexia in 18 of 26 lambs, and a transient low-titred viraemia in 16 of 26 lambs after inoculation, no untoward effects were observed. Serum-neutralizing antibody to RVFV was detected 5-7 days after inoculation. Lambs vaccinated with either 5 × 105 or 5 × 103 p.f.u. of RVF MP-12 were protected against virulent RVFV challenge at 14 days postvaccination.

AB - A previous study demonstrated that a mutagen-attenuated Rift Valley fever virus (RVFV) vaccine, RVF MP-12, was immunogenic and non-abortogenic when ewes, 90 110 days pregnant, were inoculated with 5 × 105 plaque-forming units (p.f.u.) of the virus strain. The ewes delivered live, healthy lambs that had no neutralizing antibody to RVFV until after they had ingested colostrum. To assess further the safety and protective capability of this candidate vaccine, six pregnant ewes were inoculated with 5 × 103 p.f.u. of RVF MP-12 and challenged with 5 × 105 p.f.u. of virulent ZH-501 strain of RVFV 30 days later. No viraemia was detected after vaccination or challenge and all six ewes delivered live, healthy lambs. Those lambs tested before their nursing did not have neutralizing antibody to RVFV but quickly acquired antibody titres of 1:320 to ≥ 1:10 240 after ingesting colostrum. To test the safety of the RVF MP-12 immunogen in neonates, lambs ≤ 7 days old, born to unvaccinated ewes, were inoculated with 5 × 105 p.f.u. of RVF MP-12. With the exception of brief pyrexia in 18 of 26 lambs, and a transient low-titred viraemia in 16 of 26 lambs after inoculation, no untoward effects were observed. Serum-neutralizing antibody to RVFV was detected 5-7 days after inoculation. Lambs vaccinated with either 5 × 105 or 5 × 103 p.f.u. of RVF MP-12 were protected against virulent RVFV challenge at 14 days postvaccination.

KW - attenuated

KW - mutagen

KW - Rift Valley fever

KW - sheep

KW - vaccine

UR - http://www.scopus.com/inward/record.url?scp=0026062243&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026062243&partnerID=8YFLogxK

U2 - 10.1016/0264-410X(91)90314-V

DO - 10.1016/0264-410X(91)90314-V

M3 - Article

C2 - 2008798

AN - SCOPUS:0026062243

VL - 9

SP - 35

EP - 41

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 1

ER -